IL1B and influenza: Regarding the administration of non-live vaccines in patients undergoing anti-IL-1 therapies, Chiato et al. evaluated the efficacy of inactivated adjuvated influenza (Agrippal) and meningococcal group C conjugate (MenC) vaccinations in healthy patients exposed (<2 weeks before vaccinations) to a single 300 mg dose of canakinumab (a fully human monoclonal antibody neutralizing IL-1β) [45].